Minerva Neurosciences, Inc. 8-K

What Happened

• Minerva Neurosciences, Inc. filed an 8-K on May 27, 2026 announcing a Sales Agreement with Leerink Partners LLC to conduct an "at-the-market" (ATM) equity offering. Under a related prospectus supplement, the company may sell up to $75.0 million of common stock from time to time pursuant to its effective Form S-3 (File No. 333-294203).
• The company also updated a clinical program: the Phase 3 C19 trial of roluperidone for negative symptoms of schizophrenia will extend its relapse assessment phase from 40 weeks to 52 weeks following additional FDA feedback. Topline 12‑week efficacy results are still expected in the second half of 2027; relapse assessment data are expected in the second half of 2028.

Key Details

• ATM program: up to $75.0 million aggregate offering price; sales handled through Leerink Partners LLC; agent commission is 3.0% of gross proceeds.
• Registration: sales to be made under the company’s Form S-3 registration statement (effective March 19, 2026) and the Prospectus Supplement dated May 27, 2026.
• ATM mechanics: sales may be effected as "at-the-market" offerings under Rule 415(a)(4); Minerva is not obligated to sell shares and Leerink is not required to sell any specific amount; either party can suspend or terminate the agreement with notice.
• Phase 3 trial specifics: primary efficacy assessed at 12 weeks; relapse phase now 52 weeks with patients crossing over to daily 64 mg roluperidone or antipsychotics; expected topline results H2 2027 and relapse data H2 2028.

Why It Matters

• Financing flexibility: the ATM gives Minerva a ready mechanism to raise up to $75M as needed without a single large follow-on offering. Any ATM sales would dilute existing shareholders and incur a 3% sales commission. The company has no obligation to sell under the program.
• Clinical timeline impact: extending the relapse assessment to 52 weeks delays the availability of relapse data to H2 2028, which is important for investors tracking regulatory milestones and commercialization timelines for roluperidone. Both the ATM and the extended trial timeline are material to the company’s cash needs and planning.
• Risk reminder: the filing reiterates customary forward-looking statement risks, including regulatory interactions (FDA), trial outcomes and timing, and potential future financing needs.